{
    "organizations": [],
    "uuid": "39ab3db6db18611084900f07626efe52ec852141",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aevi-genomic-medicine-expands-coll/brief-aevi-genomic-medicine-expands-collaboration-with-kyowa-hakko-kirin-co-idUSFWN1QP0KR",
    "ord_in_thread": 0,
    "title": "BRIEF-Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Aevi Genomic Medicine Inc:\n* AEVI GENOMIC MEDICINE INC - EXPANDED COLLABORATION WITH KYOWA HAKKO KIRIN CO LTD\n* AEVI GENOMIC MEDICINE - SIGNING OF OPTION AGREEMENT FOR EARLY STAGE MONOCLONAL ANTIBODY PROGRAM IN AN ULTRA-ORPHAN PEDIATRIC INDICATION\n* AEVI GENOMIC MEDICINE INC - FINANCIAL AND OTHER TERMS OF DEAL WERE NOT DISCLOSED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T21:20:00.000+02:00",
    "crawled": "2018-03-08T17:34:31.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "aevi",
        "genomic",
        "medicine",
        "inc",
        "aevi",
        "genomic",
        "medicine",
        "inc",
        "expanded",
        "collaboration",
        "kyowa",
        "hakko",
        "kirin",
        "co",
        "ltd",
        "aevi",
        "genomic",
        "medicine",
        "signing",
        "option",
        "agreement",
        "early",
        "stage",
        "monoclonal",
        "antibody",
        "program",
        "pediatric",
        "indication",
        "aevi",
        "genomic",
        "medicine",
        "inc",
        "financial",
        "term",
        "deal",
        "disclosed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}